Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Mass Spec on Mars | Main | Family Portraits »

October 26, 2006

It Should Work. It Just Doesn't.

Email This Entry

Posted by Derek

The late-stage clinical failure of a small company/big company drug partnership story gets told over and over, and today it was the turn of Renovis and AstraZeneca. Renovis had come up with a candidate (NXY-059) for post-stroke therapy that targeted free-radical oxidative damage. Initial clinical trials were fairly positive, but this latest one, a larger and more rigorous effort, totally failed to demonstrate any benefits for the drug.

They've got plenty of company. I've lost count of the number of neuroprotective drug candidate failures I've heard about during my time in industry. It's humbling, like much of drug discovery is when you look at it closely. I mean, if you get your information from the newspapers or (God help you) television news segments, you'd think that we know just how tissues are damaged after an event like a stroke, which means we know just how to block the process, so all it takes it just sending in some drug to keep it from happening. The folks in the lab coats should be whipping one right out any day now.

Nope. Hasn't worked out. Excitatory glutamate toxicity for example, was all the rage about ten years ago, but a number of Phase II and III wipeouts showed that even if these drugs could work (a big if), they would have to be given very, very quickly, which isn't clinically realistic. Since that run of failures, a new set of standards were developed to try to improve the quality of clinical candidates and trials in the field. The Renovis drug is one of the first to come in under those criteria, but little good did they do in this case. Neuroprotection is hard.

Comments (6) + TrackBacks (0) | Category: Cardiovascular Disease | Clinical Trials | The Central Nervous System


COMMENTS

1. Alastair on October 27, 2006 1:59 AM writes...

Did anything come of any Maxi-K programmes for stroke?

Permalink to Comment

2. Alastair on October 27, 2006 2:02 AM writes...

Did anything come of any Maxi-K programmes for stroke?

Permalink to Comment

3. Morten on October 27, 2006 4:43 AM writes...

Some guy named Walker did a Phase II of Progesterone as a neuroprotective - not for stroke but for trauma. They focused on safety rather than efficacy so it was 4:1 but it still looks encouraging. I'm looking forward to see the results of phase III...

Permalink to Comment

4. Dave H on October 27, 2006 8:38 AM writes...

Shouldn't work, but it does:

http://www.newscientist.com/article.ns?id=dn10287&feedId=online-news_rss20

Permalink to Comment

5. JC on October 27, 2006 3:59 PM writes...

That compound was first developed by a defunct company name of Centaur, in Sunnyvale, CA. That was my first job out of school (1995) Although I was geared towards synthesis they assigned me to the process group (2 guys) for awhile. And this was the stuff I was making. We had to make our own t-butyl hydroxyl amine by the 300g load! anyway we made around 28 kilos. I actually made the d-9 t-butyl hydroxyl amine (10 g of the nitro starting material to make the hydroxyl amine was $5,000) and made the nxy-059 d-9, for metabolism purposes or something.

AAnyway I left that crappy place after 18 months and subsequently they went bust, but they spun the IP (this compound) into this Renovis business.

So now it finally failed. They were dosing like 8 g (its the 3,5 bis sulfonic acid sodium salt on the phenyl ring). Frankly I am not surprised.

Permalink to Comment

6. Luke on October 28, 2006 7:29 AM writes...

The Renovis failure hit close to home at my work too. One of our now unemployed Associate Directors chose to come to work for us rather then Renovis. I suspect he made the better choice as for places to work, as while I know nothing about the people or future outlook (ok I know it is bleak for the moment, but...) there, at least here he is in Biotech City (figuratively) and knows he needs to look for a job. More succinctly put, he knows his fate, rather than dealing with further uncertainty.

Oh and Derek, thank you for the condolences. I have high hopes! It is a Bright New Day!

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi
Total Synthesis in Flow
Sweet Reason Lands On Its Face
More on the Science Chemogenomic Signatures Paper
Biology Maybe Right, Chemistry Ridiculously Wrong